Noninfectious anterior uveitis is a severe ocular inflammatory disease that can lead to blindness. Typical symptoms include pain, redness, and, in some patients, vision loss.
A class of drugs known as corticosteroids are usually prescribed to treat uveitis, but steroids are toxic, and long-term use may lead to cataracts (lens opacities), glaucoma (increased pressure inside the eye), corneal ulcerations (sores of the front of the eye), and an increased rate of eye infection.
Evidence suggests that toxic chemicals known as aldehydes are formed in patients with noninfectious anterior uveitis and may be partially responsible for the inflammation in the disease.
We announced positive data from our Phase II clinical trial of ADX-102 ophthalmic solution and started enrollment for Phase 3 in patients with noninfectious anterior uveitis. ADX-102 reduced cell count in a manner comparable to standard-of-care topical corticosteroids, which are effective but toxic, leading to glaucoma and cataracts in many patients.